See the Unseen…
Treat the Unseen…
In-Situ
See the Unseen…
Treat the Unseen…
In-Situ
About Us
OncoLux is a MedTech company advancing a novel optical theranostics platform that combines multispectral fluorescence imaging and photodynamic therapy in a single integrated system to “See and Treat” cancer during surgery.
The company’s preliminary clinical focus is on applying the technology intraoperatively during resection of advanced colorectal tumors to detect and eliminate residual disease to reduce disease recurrence after surgery.
OncoLux applies advanced photonics and AI in this platform to achieve a new level of surgical visualization and targeted intraoperative therapy compatible with minimally invasive and robotic surgical procedures.
Our Mission
To improve patient outcomes in cancer resection surgery, OncoLux is pioneering the advancement and utility of optical theranostics that enables surgeons to “See and Treat” cancer in real time. By combining advanced photonics, AI, and targeted therapy, we empower precise detection of positive margins and the elimination of local residual disease through the delivery of in-situ photodynamic therapy.
Our Technology
Enhanced optical imaging breakthroughs are poised to redefine what’s possible in the operating room, and the convergence of this new technology with AI will enable the transformation of data into actionable intelligence for surgeons. In addition, optical technologies that allow for In-Situ delivery of therapeutic solutions, combined with enhanced imaging enables a disruptive new capability to See and Treat disease In-Situ. OncoLux is bringing together both of these optical approaches to create our LUMIS™ platform.
Our Clinical Focus
Colorectal Cancer
Advanced colorectal cancer with recurrent or T4 tumors that are candidates for surgical resection
- “See and Treat” during robotic-assisted laparoscopic procedure
- Currently in Phase II (NCT06307548)
Advanced colorectal cancer with recurrent or T4 tumors that are candidates for surgical resection
“See and Treat” during robotic-assisted laparoscopic procedure
Currently in Phase II (NCT06307548)
Lung Cancer
Patients with suspicious peripheral lung nodules after CT scan that are undergoing biopsy via robotic bronchoscopy
- “See and Treat” during robotic bronchoscopy
- First-In-Human clinical study 2027
Patients with suspicious peripheral lung nodules after CT scan that are undergoing biopsy via robotic bronchoscopy
“See and Treat” during robotic bronchoscopy
First-In-Human clinical study 2027
Team: Strong track record of execution
The multidisciplinary OncoLux team has decades of experience in the photonics industry, with expertise in systems engineering and commercialization of new technology.
ALAN KERSEY
CEO
TREVOR MACDOUGALL
VP & COO
PAUL SANDERS
Advisor-Clinical Affairs
SCOTT NELSON
Manager, Clinical Operations
DAVID FOURNIER
Advisor - Technology
Advisors: Extensive experience in MedTech Strategy, Commercialization & Regulatory
PETER TRAIANOU
Surgical Robotics
DAVID UFFER
Medical Devices
JASON PESTERFIELD
Corporate Strategy
LORI SWALM
Regulatory Advisor
Collaborators and Investors
Join us and be a part of our success.
At OncoLux, we are looking for individuals interested in shaping the future of surgery through innovative AI-powered imaging solutions.